Compare Deutsche Bank AG (DB) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs GSK plc — how do they compare? Deutsche Bank AG trades at $33.77 (market cap $63.13B), while GSK plc trades at $46.7 (market cap $95.18B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.86%). Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and GSK plc for 93 Days on average.
| DB | GSK | |
|---|---|---|
Market Cap | $63.13B | $95.18B |
Volume | 3,260,488 | 5,852,596 |
Sector | Financials | Health |
52-Week High | $41.56 | $61.18 |
52-Week Low | $28.37 | $43.24 |
Typical Hold Time | 80 Days | 93 Days |
Enterprise Value | $75.71B | $115.25B |
Dividend Yield | 3.47% | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.63, down 4.27% amid a bearish technical signal. The stock shows attractive valuation with a P/E of 9.1 and P/B of 0.71, while recent earnings beat expectations in two of the last three quarters. Net income surged to $6.93B in 2025, though Q3 2026 investment bank revenue is expected flat to slightly down. Cash flow improved significantly with net cash flow of $7.61B in 2025.
The outlook is mixed: strong fundamentals and low valuation support upside, but bearish technicals and cautious analyst consensus (57.58% hold) indicate near-term headwinds. Key risks include revenue volatility in investment banking and macroeconomic sensitivity. The stock offers value potential if execution on 2028 targets holds.
GSK trades at $46.54, down 0.13% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 15.1 and EV/EBITDA of 9.0. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for growth beyond upcoming HIV patent expirations.
GSK presents a balanced investment case with solid profitability (29.7% ROE) offset by near-term headwinds. The stock offers value at current levels but faces execution risks from pipeline development and patent cliffs. Analyst sentiment leans cautious with 55% hold ratings, suggesting moderate upside potential with careful risk management required.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
